And these "momo" stocks are the ones that ultimately flop. I would much more prefer a value based proposition. PTN has improved its capital significantly with the licensening deals and it may continue to improve if they can sign Europe and other regions. My issue is about perspective. They still have not filed the NDA and even once this is submitted, they will have to wait 6-10 months for actual approval...and this is if the FDA accepts the original package/submission. Translation, they will not receive any revenue until 2019 at the earliest from Brem. The near term drives of value will be more licensening and initial work on other candidates. Spana has proven countless times he is good at one thing beyond reproach and that is burning cash. While I suspect the warrants have been dumped to a large part during the recent trading/action, it will add to the float. They are out to J warrants at last count and have utulized over half of the authorized, so the share structure while alright, could be shored up. In short, PTN, needs to watch expenses while still driving future value for any shareholders....Spana is the master of dilutive financing.....this is fact.
News 
Market Data 
Discover 
